<DOC>
	<DOCNO>NCT01389206</DOCNO>
	<brief_summary>This program intend improve management pulmonary arterial hypertension ( PAH ) patient evidence-based approach aim achieve optimal World Health Organization ( WHO ) functional class ( FC ) : 1 . Improving FC III &amp; IV patient FC II , 2 . Improving FC II patient FC I , 3 . Maintaining FC II &amp; FC I patient .</brief_summary>
	<brief_title>Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<criteria>1 . Male female adult ( &gt; /= 18 year age ) 2 . Documented diagnosis pulmonary arterial hypertension ( PAH ) ( follow ) : Right Heart Catheterization ( RHC ) demonstrate mean Pulmonary Arterial Pressure ( mPAP ) &gt; 25mm Hg Pulmonary Capillary Wedge Pressure ( PCWP ) &lt; = 15 PVR &gt; 3 Forced Expiratory Volume first second ( FEV1 ) &gt; 50 % predict normal Ventilation/Perfusion ( V/Q ) and/or Computerized Tomography ( CT ) scan exclude thromboembolic etiology 3 . Diagnosis PAH &lt; 3 year 4 . Need PAH specific treatment 5 . Desire participate sign Informed Consent . Any criterion : Poor mental function , drug substance ( e.g. , alcohol ) abuse , unstable psychiatric illness , , opinion investigator , may interfere optimal participation study Prior participation program Patients Pulmonary Hypertension ( PH ) classify group 2 5 Updated Clinical Classification PH ( 5th World Symposium PH Modified Classification PH ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>